Biophotonics market is estimated to increase in the future
All analysts forecast that the Biophotonics market is going to increase, but biophotonics products seem to encounter hurdles in the adoption.
As depicted in the article titled: Biophotonics Market Growth Reliant on Increasing Adoption of Light Therapy and Microscopy published by Bloomberg
How to overcome these hurdles:
FORGING ALLIANCES
Market players are forging alliances with other top healthcare companies to maintain their position in the industry.
In June 2021, Alberta Biophotonics Inc. announced the acquisition of additional shares of Flurotech Limited, pursuant to a three-cornered amalgamation between FluroTech, FluroTest Systems Ltd. and 2330853 Alberta Ltd.
EXPANSION OF PRODUCT PORTFOLIO/NEW PRODUCT LAUNCHES
PhotoniCare Inc. announced the funding of more than US$ 7 million to commercially expand its imaging technology, TOMi Scope.
In May 2021, Olympus America announced the launch and clearance of its BF-UC190F endobronchial ultrasound (EBUS) bronchoscope, a new addition to its EBUS portfolio of devices for lung cancer diagnosis and staging via needle biopsy.
Increasing investment and funding for biomedical imaging and initiatives for research & development are providing lucrative opportunities for the market players.
The Chan Zuckerberg Initiative (CZI) announced funding of nearly US$ 32 million for biomedical imaging research, technology development, and the BioImaging North America international network of bioimaging facilities & communities.

Comments
Post a Comment